HomeProductsBioactive CompoundsApoptosisIAPXevinapant
Chemical structure of CAS 1071992-99-8

Xevinapant

CAS No.1071992-99-8
MDL No.MFCD22124467
MFC32H43N5O4
MW561.70
InChI KeyLSXUTRRVVSPWDZ-MKKUMYSQSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1071992-99-8
Product NameXevinapant

Associated Conditions

malignant glioma·cancer·acute myeloid leukemia·non-small cell lung carcinoma·head and neck squamous cell carcinoma·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.

Journal of medicinal chemistry • Vol. 54, Issue 8 • 2011
PMID: 21443232PMC: PMC3520070DOI: 10.1021/jm101505d

Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis.

Cancer cell • Vol. 12, Issue 5 • 2007
PMID: 17996648PMC: PMC3431210DOI: 10.1016/j.ccr.2007.08.029

Smac mimetics and TNFalpha: a dangerous liaison?

Cell • Vol. 131, Issue 4 • 2007
PMID: 18022360PMC: PMC3184251DOI: 10.1016/j.cell.2007.10.042

Documentation